Cadrenal Therapeutics gains FDA alignment on CAD-1005 Phase 3 design
Cadrenal Therapeutics has secured regulatory alignment with the US Food and Drug Administration on the core design elements of its planned Phase 3 registration study of CAD-1005, a novel 12-lipoxygenase (12-LOX) inhibitor in development for heparin-induced thrombocytopenia (HIT). The Nasdaq-listed company said the outcome of a Type D meeting held on 28 July 2026 clears a significant hurdle on the path toward a pivotal trial.
HIT is an immune-mediated reaction to heparin, one of the most widely used anticoagulants in hospital settings, and can trigger paradoxical, life-threatening blood clot formation. The condition affects an estimated 50,000 patients a year in the United States. Existing treatments manage thrombotic risk through alternative anticoagulants but do not address the underlying immune cascade. CAD-1005 is intended to be layered on top of standard anticoagulation rather than replace it, targeting the 12-LOX enzyme pathway that drives platelet activation in HIT.
Primary endpoint and trial structure
The FDA agreed on a refined composite primary endpoint: the proportion of patients who test positive on the Serotonin Release Assay (SRA) and experience adjudicated new or worsening composite thromboembolic events through Day 14 of treatment or hospital discharge, whichever comes first. Critically, the worsening definition will include extension of an existing thrombus into a new vascular segment, a specification the agency introduced to reduce variability arising from manual thrombus-size measurements across clinical sites.
The FDA also agreed to a placebo-controlled design in which both arms receive standard anticoagulation, with CAD-1005 or saline added on top. Bleeding will be assessed as a major safety endpoint using International Society on Thrombosis and Haemostasis criteria, applied to all patients who receive at least one dose of study drug.
Chief executive Quang X. Pham said the meeting delivered "collaborative, constructive feedback" and that the company has incorporated the agency's recommendations into its protocol and Statistical Analysis Plan, adding: "We have incorporated the Agency's recommendations into our Phase 3 protocol and Statistical Analysis Plan, strengthening the design of a registration study intended to evaluate whether CAD-1005 can reduce dangerous thrombotic events that persist in patients with HIT despite current anticoagulant therapies."
Market context and competitive landscape
The acute HIT market is a narrow but high-value indication. Approved alternatives to heparin in HIT patients include argatroban and bivalirudin, both of which work solely through anticoagulation. No approved therapy currently targets the immunological underpinning of the condition, which gives CAD-1005 a mechanistically distinct position if the Phase 3 trial delivers. Cadrenal puts peak annual revenue potential at $2 billion, though this is an early company projection with no commercial or partnership infrastructure yet disclosed.
CAD-1005 holds FDA Orphan Drug Designation and Fast Track designation for HIT, as well as an orphan designation from the European Medicines Agency. The Orphan Drug pathway could yield seven years of market exclusivity in the US upon approval, a commercial protection that tends to attract acquirer interest in small-cap rare-disease companies. Cadrenal also holds a second-generation oral 12-LOX programme, CAD-2000, in earlier development for chronic indications, which broadens the platform thesis for prospective partners.
The company has not disclosed a Phase 3 start date, patient enrolment target, or partnering status. Investors will be watching for the ClinicalTrials.gov registration and a timeline for first patient dosing as the next concrete milestones.